<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04537520</url>
  </required_header>
  <id_info>
    <org_study_id>2018-A01743-52</org_study_id>
    <nct_id>NCT04537520</nct_id>
  </id_info>
  <brief_title>Interventional Clinical Trial Comparing Kerecis Omega3 Wound Versus SOC in Diabetic Foot Wounds</brief_title>
  <acronym>KereFish</acronym>
  <official_title>Interventional Multi-Center Post Market Randomized Controlled Open-Label Clinical Trial Comparing Kerecis Omega3 Wound Versus SOC in Hard to Heal Diabetic Foot Wounds</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre d'Etudes et de Recherche pour l'Intensification du Traitement du Diabète</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kerecis Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>RCTs</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Clininfo S.A.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre d'Etudes et de Recherche pour l'Intensification du Traitement du Diabète</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The KereFish study is a randomized controlled study to study the efficacy of Kerecis Omega3&#xD;
      Wound on deep diabetic ulcers. This study is probably the first in his field: in this one,&#xD;
      the Kerecis Omega3 Wound dies are used on the types of wounds for which they are ultimately&#xD;
      intended. This study aims to document the cost benefits of earlier closure of severe diabetic&#xD;
      wounds, or the change of the deep and chronic wound into a smaller and shallower ulcer, and&#xD;
      to radically alter its prognosis. The study, carried out in France, uses the pre-existing&#xD;
      home nursing system with the transmission of photographs to the reference centre. The study&#xD;
      was largely designed to ensure transparency of the financial calculations involved.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 2, 2020</start_date>
  <completion_date type="Anticipated">December 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Wound area</measure>
    <time_frame>Week 0</time_frame>
    <description>measuring the surface of the wound with planimetry software</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Wound area</measure>
    <time_frame>Week 16</time_frame>
    <description>measuring the surface of the wound with planimetry software</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">229</enrollment>
  <condition>Diabetes</condition>
  <condition>Diabetic Foot Ulcer</condition>
  <arm_group>
    <arm_group_label>Experimental Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>treatment with the device Kerecis Omega3 Wound</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>treatment with SOC treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Kerecis Omega3 Wound</intervention_name>
    <description>Treatment of the wound with Kerecis Omega3 Wounds matrices</description>
    <arm_group_label>Experimental Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diabetic patients, regardless of the age of their diabetes, with a grade UT 2 or 3&#xD;
             lower limb sore; grade 2: wound penetrating to the tendon or capsule. UT grade 3:&#xD;
             wound penetrating to the bone or joint OR hospitalized/ambulatory patients for&#xD;
             diabetic foot sores or amputations, which have not closed or are dehiscent.&#xD;
&#xD;
          -  Patients who can tolerate aggressive surgical debridement&#xD;
&#xD;
          -  Patients without severe ischemia IPS - 0.6 or pressure of the big toe - 50mmHg&#xD;
&#xD;
          -  Longness of the wound: 30 days (does not apply to amputation wounds; patients may be&#xD;
             included when the wound is less than 30 days old) OR if the amputation level is under&#xD;
             the ankle&#xD;
&#xD;
          -  Patients willing and able to give informed consent to participate in the clinical&#xD;
             trial.&#xD;
&#xD;
          -  Male or female over the age of 18&#xD;
&#xD;
          -  Patients living at a geographical distance compatible with referral nurse visits&#xD;
&#xD;
          -  Negative pregnancy test for women of childbearing age who do not use contraception.&#xD;
&#xD;
          -  Patients covered by social security&#xD;
&#xD;
          -  Patients who are capable (in the investigator's opinion) and willing to comply with&#xD;
             all clinical trial requirements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients whose wound surface is not measurable&#xD;
&#xD;
          -  Patients with unsealed osteomyelitis&#xD;
&#xD;
          -  Patients with fever related to a foot infection (it may be reassessed at a later time&#xD;
             when the infection is gone)&#xD;
&#xD;
          -  Patients with a necrotic wound that will not tolerate aggressive surgical debridement&#xD;
&#xD;
          -  Immunosuppressed patients&#xD;
&#xD;
          -  Patients with systemic corticosteroids or other treatments that may delay wound&#xD;
             healing&#xD;
&#xD;
          -  Pregnant, breast-feeding or planning pregnancy during the clinical trial&#xD;
&#xD;
          -  Any other significant disease or disorder that the investigator believes may pose a&#xD;
             risk to participants because of their participation in the clinical trial or that may&#xD;
             influence the outcome of the clinical trial or the participant's ability to&#xD;
             participate in the clinical trial.&#xD;
&#xD;
          -  Patients with rheumatoid arthritis&#xD;
&#xD;
          -  Patients with systemic lupus&#xD;
&#xD;
          -  Patients with a known skin allergy to fish&#xD;
&#xD;
          -  Patients deprived of liberty by judicial or administrative decision, persons subject&#xD;
             to a legal protection measure&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dured DARDARI, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Sud Francilien</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laurent Orlando</last_name>
    <phone>+33160878922</phone>
    <email>laurent.orlando@ceritd.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dina INGRAO LECANTE</last_name>
    <phone>+33160878926</phone>
    <email>dina.ingrao-lecante@ceritd.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU de Caen</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Julia MORERA</last_name>
      <phone>+33231065185</phone>
      <email>morera-j@chu-caen.fr</email>
    </contact>
    <investigator>
      <last_name>Julia MORERA</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne ROD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Sud Francilien</name>
      <address>
        <city>Corbeil-Essonnes</city>
        <zip>91100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dured DARDARI</last_name>
      <phone>+33160903086</phone>
      <email>dured.dardari@chsf.fr</email>
    </contact>
    <investigator>
      <last_name>Dured DARDARI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Dijon - Bocage Sud</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Benjamin BOUILLET</last_name>
      <phone>+33380293453</phone>
      <email>benjamin.bouillet@chu-dijon.fr</email>
    </contact>
    <investigator>
      <last_name>Benjamin Bouillet</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Michel Petit</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Coralie Fourmont</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexia Rouland</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antoine Hourdin</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Estelle Charpin</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hotel Dieu Le Creusot</name>
      <address>
        <city>Le Creusot</city>
        <zip>71200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sylvaine Clavel</last_name>
      <phone>+33385777470</phone>
      <email>clavel.sylvaine@wanadoo.fr</email>
    </contact>
    <investigator>
      <last_name>Sylvaine Clavel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ariane Sultan</last_name>
      <phone>+33467338431</phone>
      <email>a-sultan@chu-montpellier.fr</email>
    </contact>
    <investigator>
      <last_name>Ariane Sultan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Cochin</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jocelyne M'Bemba</last_name>
      <phone>+33158412317</phone>
      <email>jocelyne.mbemba@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Jocelyne M'Bemba</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Bichat-Claude Bernard</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ronan ROUSSEL</last_name>
      <phone>+33140256547</phone>
      <email>ronan.roussel@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Ronan ROUSSEL</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Reims - Hôpital Debré</name>
      <address>
        <city>Reims</city>
        <zip>51100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maud Francois</last_name>
      <phone>+33326787154</phone>
      <email>mfrancois@chu-reims.fr</email>
    </contact>
    <investigator>
      <last_name>Maud François</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital de Roubaix - CETRADIM</name>
      <address>
        <city>Roubaix</city>
        <zip>59100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marc Lepeut</last_name>
      <phone>+33320993041</phone>
      <email>marc.lepeut@ch-roubaix.fr</email>
    </contact>
    <investigator>
      <last_name>Marc Lepeut</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes Hôpital Nord Laennec</name>
      <address>
        <city>Saint Herblain</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lucy Chaillous</last_name>
      <phone>+33240083333</phone>
      <email>lucy.chaillous@chu-nantes.fr</email>
    </contact>
    <investigator>
      <last_name>Lucy Chaillous</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU de Strasbourg - Hopital Civil</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laurence Kessler</last_name>
      <phone>+33388116267</phone>
      <email>laurence.kessler@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>Laurenxe Kessler</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ionela Stifii</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Toulouse Hôpital Rangueil</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jacques Martini</last_name>
      <phone>+33561322149</phone>
      <email>martini.j@chu-toulouse.fr</email>
    </contact>
    <investigator>
      <last_name>Jacques Martini</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 25, 2020</study_first_submitted>
  <study_first_submitted_qc>September 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 3, 2020</study_first_posted>
  <last_update_submitted>September 2, 2021</last_update_submitted>
  <last_update_submitted_qc>September 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Complex diabetic foot wounds</keyword>
  <keyword>Kerecis Omega3Wound</keyword>
  <keyword>extracellular matrix</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetic Foot</mesh_term>
    <mesh_term>Foot Ulcer</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

